{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:27:54Z","timestamp":1795044474644,"version":"4.10.2"},"reference-count":146,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/17425247.2023.2219053","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:36:27Z","timestamp":1685457387000},"page":"905-919","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":56,"title":["Sustained release ocular drug delivery systems for glaucoma therapy"],"prefix":"10.1080","volume":"20","author":[{"given":"Zinah K.","family":"Al-Qaysi","sequence":"first","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC) Theme, Department of Pharmacy, Kingston University London, Kingston Upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian G.","family":"Beadham","sequence":"additional","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC) Theme, Department of Pharmacy, Kingston University London, Kingston Upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sianne L.","family":"Schwikkard","sequence":"additional","affiliation":[{"name":"Department of Chemical and Pharmaceutical Sciences, Kingston University, Kingston Upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Bear","sequence":"additional","affiliation":[{"name":"Department of Chemical and Pharmaceutical Sciences, Kingston University, Kingston Upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Al-Kinani","sequence":"additional","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC) Theme, Department of Pharmacy, Kingston University London, Kingston Upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid G.","family":"Alany","sequence":"additional","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC) Theme, Department of Pharmacy, Kingston University London, Kingston Upon Thames, UK"},{"name":"School of Pharmacy, The University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"1","key":"cit0001","first-page":"S19","volume":"59","author":"Pan Y","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.02.003"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics4010197"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.7.691"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101817"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.06.002"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-29265-1_9"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(97)00002-5"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2017.07.001"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44708"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1159\/000458482"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2174\/156652410793937778"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-019-00210-3"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.015"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.012"},{"key":"cit0017","volume-title":"Clinical pharmacy and therapeutics E-Book","author":"Walker R","year":"2011","edition":"5"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.026"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.035"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.4103\/jovr.jovr_35_18"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00002"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2557-4"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000334"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2021.01.21"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldv002"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-015-8494-8"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059030-00003"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0067"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.03.003"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.10.004"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1963.00960050304004"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.10.031"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0159-x"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.36348\/sjmps.2020.v06i05.005"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100901"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00014-X"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S109708"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113957"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/895013"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.15713\/ins.clever.24"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09379-8"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S48766"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.04.022"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2016.1138342"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1080\/09205063.2020.1712175"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.06.001"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.09.032"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1021\/nn5002968"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b11655"},{"issue":"13","key":"cit0051","first-page":"5816","volume":"48","author":"Leahy C","year":"2007","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S102181"},{"issue":"9","key":"cit0053","first-page":"5675","volume":"59","author":"Utkhede D","year":"2018","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.11.020"},{"key":"cit0055","unstructured":"Allergan Receives FDA Approval for DURYSTA\u2122 (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients. 3 May 2020 [cited 2020 Apr 8]; Available from: https:\/\/www.allergan.com\/News\/Details\/2020\/03\/Allergan%20Receives%20FDA%20Approval%20for%20DURYSTA%20bimatoprost%20implant%20the%20First%20and%20Only%20Intracameral%20Biode."},{"issue":"13","key":"cit0056","first-page":"3548","volume":"55","author":"Navratil T","year":"2014","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0057","unstructured":"Envisia therapeutics releases interim ENV515 (travoprost XR) phase 2 data demonstrating 11-month duration-of-action after a single dose in patients with glaucoma feb 03, 2017, 07: 45 ET [cited 2020 Apr 10]; Available from: https:\/\/www.prnewswire.com\/news-releases\/envisia-therapeutics-releases-interim-env515-travoprost-xr-phase-2-data-demonstrating-11-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma-300401812.html."},{"issue":"13","key":"cit0058","first-page":"5270","volume":"55","author":"Trevino L","year":"2014","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0059","unstructured":"Ocular Therapeutix OTX-TP trial misses primary endpoint. May 22, 2019 [cited 2020 Apr 21]; Available from: https:\/\/www.drugdeliverybusiness.com\/ocular-therapeutix-otx-tp-trial-misses-primary-endpoint\/."},{"key":"cit0060","unstructured":"Glaukos presentation.Published in: Investor Relations.Presented at: 18:31:51 UTC; 2018. [cited 2020 Apr 8]; Available from: https:\/\/www.slideshare.net\/glaukos\/glaukos-january-2018-presentation."},{"key":"cit0061","unstructured":"Glaukos Corporation\u2019s iDose\u2122 Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort. Jan 10, 2018 [cited 2020 Apr 8]; Available from: http:\/\/investors.glaukos.com\/investors\/press-releases\/press-release-details\/2018\/Glaukos-Corporations-iDose-Travoprost-Achieves-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-in-12-Month-Interim-Cohort\/default.aspx."},{"issue":"8","key":"cit0062","first-page":"4591","volume":"58","author":"Komaromy AM","year":"2017","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.11.008"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19585"},{"key":"cit0065","unstructured":"pSivida Announces Phase I\/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma. Watertown, Mass. Jun 14, 2011 [cited 2020 Apr 10]; Available from: https:\/\/www.pfizer.com\/files\/partnering\/061411_psivida_announces_phase_clinical_study.pdf."},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14024"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.07.012"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10371"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.5497\/wjp.v2.i2.47"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0328-0"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-47691-9_5"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.10.069"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1039\/D1BM01453F"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.12.017"},{"key":"cit0075","volume-title":"Several groups are working to overcome challenges inherent to drop therapy","author":"The Pipeline","year":"2018"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24030603"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2014.06.013"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.15406\/japlr.2016.02.00022"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(98)00087-X"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.3109\/02652048.2015.1134685"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-014-0196-6"},{"key":"cit0082","volume-title":"Remington: the science and practice of pharmacy","volume":"1","author":"Remington JP","year":"2006"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2016.01.008"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.08.037"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2022.2055063"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.026"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-010-9362-3"},{"issue":"2","key":"cit0088","first-page":"164","volume":"1","author":"Rathore K","year":"2009","journal-title":"Int J Pharmtech Res"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.4103\/0973-8398.45031"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.4103\/0110-5558.72419"},{"key":"cit0091","unstructured":"A study to evaluate efficacy and safety of a fixed combination ocular insert in participants with open-angle glaucoma or ocular hypertension. [cited 2021 3 March]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02742649?view=results."},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304064"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(00)00090-4"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1088\/2515-7639\/aaf263"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.15406\/ppij.2017.05.00119"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420905740"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.3390\/ma12020261"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8020014"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.01.023"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0212"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.11.036"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.06.016"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.4155\/tde.14.73"},{"key":"cit0104","unstructured":"Mati Therapeutics Inc. Announces initiation of phase II study to compare latanoprost punctal plug delivery system (L-PPDS) to timolol eye drops. Oct. 28, 2013 [cited Jul, 11, 2020; Available from: https:\/\/www.globenewswire.com\/news-release\/2013\/10\/28\/584072\/10054563\/en\/Mati-Therapeutics-Inc-Announces-Initiation-of-Phase-II-Study-to-Compare-Latanoprost-Pu."},{"key":"cit0105","unstructured":"Development, what differentiates TODDD\u2122 from other sustained delivery technologies in development? 2017-18, amorphex therapeutics LLC [cited 2020 Apr 15]; Available from: https:\/\/www.amorphexusa.com\/development."},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0241"},{"issue":"15","key":"cit0107","first-page":"5073","volume":"54","author":"Crawford K","year":"2013","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0108","unstructured":"Platform technology transforming ocular drug delivery. [cited 2020 3 Mar]; Available from: https:\/\/www.liviakis.com\/wp-content\/uploads\/2016\/02\/Amorphex-Deck-2016.pdf."},{"key":"cit0109","volume-title":"Sustained-release drug delivery: closer than you think!","author":"Varma DK","year":"2018"},{"key":"cit0110","unstructured":"Ocular TherapeutixTM completes end-of-phase 2 review with FDA for OTX-TP (Sustained release travoprost) for glaucoma and ocular hypertension). Apr 27, 2016 [cited Jul 10, 2020]; Available from: https:\/\/www.businesswire.com\/news\/home\/20160427006688\/en\/Ocular-TherapeutixTM-Completes-End-of-Phase-2-Review-FDA."},{"key":"cit0111","unstructured":"Punctal plug drug delivery attractive method for managing glaucoma. Nov 11, 2017. [cited Jul 11, 2020]; Available from: https:\/\/www.ophthalmologytimes.com\/view\/punctal-plug-drug-delivery-attractive-method-managing-glaucoma."},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1399-2_2"},{"key":"cit0113","unstructured":"Inc Q QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System. 2010 [cited Jul, 10, 2020]; Available from: https:\/\/www.globenewswire.com\/fr\/news-release\/2010\/03\/10\/416107\/186272\/en\/QLT-Announces-Phase-II-Clinical-Trial-Results-and-Development-Plans-for-the-Punctal-Plug-Delivery-System.html."},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-47691-9"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.82"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.138"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1159\/000050849"},{"key":"cit0118","volume-title":"Bimatoprost implant: first approval","author":"Shirley M","year":"2020"},{"issue":"4","key":"cit0119","first-page":"317","volume":"6","author":"Haghjou N","year":"2011","journal-title":"J Ophthalmic Vis Res"},{"key":"cit0120","unstructured":"Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension. Jan 07, 2019 [cited Jul 14, 2020]; Available from: https:\/\/www.prnewswire.com\/news-releases\/allergan-announces-positive-3-month-topline-results-from-second-phase-3-study-of-bimatoprost-sr-sustained-release-implant-for-lowering-intraocular-pressure-iop-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-300773602.html."},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12522"},{"key":"cit0122","first-page":"10","volume":"48","author":"Navratil T","year":"2014","journal-title":"ONdrugDelivery"},{"issue":"7","key":"cit0123","first-page":"5026","volume":"56","author":"Williams S","year":"2015","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"15","key":"cit0124","first-page":"5045","volume":"54","author":"Thumann G","year":"2013","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0125","unstructured":"Sustained Release Technology. May 3, 2018, [cited Jul 15, 2020; Available from: https:\/\/aeriepharma.com\/rd\/pipeline\/drug-delivery\/."},{"issue":"7","key":"cit0126","first-page":"5706","volume":"56","author":"Navratil T","year":"2015","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0127","unstructured":"Envisia Therapeutics\u2019 Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial. 2015 [cited Jul, 17, 2020]; Available from: https:\/\/www.prnewswire.com\/news-releases\/envisia-therapeutics-lead-product-candidate-env515-travoprost-xr-achieves-primary-efficacy-endpoint-in-phase-2a-glaucoma-clinical-trial-300154705.htm."},{"issue":"7","key":"cit0128","first-page":"1242","volume":"61","author":"Langh J","year":"2020","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"9","key":"cit0129","first-page":"3777","volume":"60","author":"Blizzard CD","year":"2019","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0130","unstructured":"Ocular Therapeutix\u2122 Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma 2019 [cited Jul, 16, 2020]; Available from: https:\/\/www.biospace.com\/article\/releases\/ocular-therapeutix-announces-topline-results-of-ph."},{"key":"cit0131","unstructured":"Enabling Site-Specific Drug Delivery. [cited Jun, 19, 2020]; Available from: https:\/\/polyactiva.com\/platform\/#:~:text=The%20polytriazole%20system%20allows%20polymeric%20prodrugs%20to%20be,liner%20thermoplastic%2C%20cross-linked%20hydrogels%20and%20branched%20polymer%20systems."},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1007\/7355_2019_92"},{"key":"cit0133","unstructured":"Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma.Full Text View-ClinicalTrials.gov. Jul 27, 2018 [cited 2020 Apr 8]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03604328."},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2020.34.s1.08817"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1016-1"},{"key":"cit0136","unstructured":"Our Technology, DurasertTM Technology. [cited 2020 Jul, 7, 2020]; Available from: https:\/\/eyepointpharma.com\/our-technology\/"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.019"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1039\/C4CE00154K"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.024"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-014-0196-9"},{"key":"cit0141","first-page":"123","volume":"7","author":"Natarajan JV","year":"2012","journal-title":"Int J Nanomed"},{"key":"cit0142","unstructured":"POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma. [cited Jul, 26, 2020; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02466399."},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.018"},{"issue":"14","key":"cit0144","first-page":"5095","volume":"53","author":"Goldberg DF","year":"2012","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0067"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e3181cd6145"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2023.2219053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T08:38:43Z","timestamp":1692261523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2023.2219053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":146,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/17425247.2023.2219053"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2023.2219053","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}